Systemic drug therapy of metastatic pancreatic cancer

The standard treatment for patients with locally advanced and metastatic pancreatic cancer was monochemotherapy using gemcitabine until 2011. For a long time the attempts to create the combinations of gemcitabine and new drugs did not lead to clinically significant increase of these patients life expectancy. Introduction of new chemotherapy regimens into clinical practice such as combination of nab-paclitaxel and FOLFIRINOX was resulted in a clinically significant increase of life expectancy. Characteristics and toxicity range of new chemotherapy regimens allow form selected mode algorithm of chemotherapy regimen for every patient based on his status, comorbidity and complications of tumor process.